SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Renin-Angiotensin-Aldosterone System
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sever, P. S
Right arrow Articles by Azizi, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sever, P. S
Right arrow Articles by Azizi, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Blood Pressure Medicines
*High Blood Pressure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Managing cardiovascular and renal risk: the potential of direct renin inhibition

Peter S Sever

International Centre for Circulatory Health, Imperial College London, UK, p.sever{at}imperial.ac.uk

Alan H Gradman

Division of Cardiovascular Diseases, The Western Pennsylvania Hospital and Temple University School of Medicine, Pittsburgh, PA, USA

Michel Azizi

Clinical Investigation Center, Hospital European Georges Pompidou and the Paris-Descartes University School of Medicine, Paris, France

Aliskiren is the first direct renin inhibitor for the treatment of hypertension. Clinical experience from studies in over 14,000 patients has shown that aliskiren, alone or in combination with other antihypertensive therapies, provides effective blood pressure lowering with a good safety and tolerability profile.The ultimate aim of antihypertensive therapy, however, is to reduce the risk of adverse cardiovascular and renal outcomes.The effect of aliskiren on surrogate markers of organ damage and clinical outcomes is being assessed in the ongoing ASPIRE HIGHER programme, the largest clinical trials programme in the cardio-renal disease area. Results from the ALOFT, AVOID and ALLAY studies suggest that aliskiren has positive effects on markers of cardiovascular and renal damage in patients with type 2 diabetes and nephropathy, heart failure and left ventricular hypertrophy.ASPIRE HIGHER also includes four large-scale studies assessing the potential outcome benefits of aliskiren, and the results of these trials will help define the clinical utility of aliskiren in the treatment of cardiovascular and renal diseases. In this article, we review the antihypertensive efficacy of aliskiren and explore its potential in the management of cardiovascular and renal risk.

Key Words: aliskiren • ASPIRE HIGHER • blood pressure • cardiac • renal • renin

References

  • Wang YR, Alexander GC, Stafford RS Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141-7.[Abstract/Free Full Text]
  • Ong KL, Cheung BM, Man YB, Lau CP, Lam KS Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75.[Abstract/Free Full Text]
  • Editorial. Hypertension: uncontrolled and conquering the world. Lancet 2007;370:539.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Euroaspire II Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-72.[Abstract/Free Full Text]
  • Gradman AH, Vivas Y. New drugs for hypertension: what do they offer? Curr Hypertens Rep 2006;8:425-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Krum H., Gilbert RE Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders. J Hypertens 2007; 25:25-35.[Web of Science][Medline] [Order article via Infotrieve]
  • Tigerstedt R., Bergman P. Niere und kreislauf (kidney and circulation). Skand Arch Physiol 1898; 8:223-38.
  • Goldblatt H., Lynch J., Hanzel R., Summerville W. Studies of the elevation of systolic blood pressure by means of renal ischemia. J Exp Med 1934;59:347-79.[Abstract]
  • Atlas SA, Rosendorff C. The renin-angiotensin system - from Tigerstedt to Goldblatt to ACE inhibition and beyond. Mt Sinai J Med 1998;65:81-6.[Medline] [Order article via Infotrieve]
  • Volpe M., Savoia C., De Paolis P., Ostrowska B., Tarasi D., Rubattu S. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002;13(suppl 3): S173-8.[Abstract/Free Full Text]
  • Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectivelydesigned overviews of randomised trials. Lancet 2003; 362:1527-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Turnbull F., Neal B., Pfeffer M. et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007;25:951-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Engeli S., Negrel R., Sharma AM Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 2000;35:1270-7.[Abstract/Free Full Text]
  • Carey RM, Siragy HM Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev 2003;24:261-71.[Abstract/Free Full Text]
  • Lavoie JL, Sigmund CD Minireview: overview of the renin-angiotensin system - an endocrine and paracrine system. Endocrinology 2003;144:2179-83.[Abstract/Free Full Text]
  • Danser AH, Deinum J. Renin, prorenin and the putative (pro)renin receptor. Hypertension 2005;46:1069-76.[Free Full Text]
  • Danser AHJ, van Kesteren CA, Bax WA et al. Prorenin, renin, angiotensinogen, and angiotensin-converting enzyme in normal and failing human hearts. Evidence for renin binding. Circulation 1997;96:220-6.[Abstract/Free Full Text]
  • Danser AH, van den Dorpel MA, Deinum J. et al. Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 1989;68:160-7.[Abstract/Free Full Text]
  • Davies L., Fulcher GR, Atkins A. et al. The relationship of prorenin values to microvascular complications in patients with insulin-dependent diabetes mellitus. J Diabetes Complications 1999;13:45-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Engeli S., Schling P., Gorzelniak K. et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol 2003;35:807-25.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Faloia E., Gatti C., Camilloni MA et al. Comparison of circulating and local adipose tissue renin-angiotensin system in normotensive and hypertensive obese subjects. J Endocrinol Invest 2002;25:309-14.[Web of Science][Medline] [Order article via Infotrieve]
  • Dahlof B., Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-53.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.[Abstract/Free Full Text]
  • Lewis EJ, Hunsicker LG, Bain RP, Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.[Abstract/Free Full Text]
  • Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.[Abstract/Free Full Text]
  • Azizi M., Menard J., Bissery A. et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004;15:3126-33.[Abstract/Free Full Text]
  • Weber MA, Giles TD Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy? Rev Cardiovasc Med 2006;7:45-54.[Web of Science][Medline] [Order article via Infotrieve]
  • Skeggs LT, Jr., Kahn JR, Lentz K., Shumway NP The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957;106:439-53.[Abstract]
  • Maibaum J., Feldman DL Renin inhibitors as novel treatments for cardiovascular disease. Expert Opin Ther Patents 2003;13:589-603.[CrossRef]
  • Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006;24:243-56.[Web of Science][Medline] [Order article via Infotrieve]
  • Menard J., Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007;25:1775-82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gradman AH, Flack JM, Arora V. et al. Suppression of the renin system by the novel orally effective direct renin inhibitor aliskiren: a pooled analysis of 1612 patients with hypertension. Circulation 2006;114:773.
  • Sealey JE, Laragh JH Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007;20:587-97.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hollenberg NK A brief response to Sealey and Laragh. J Renin Angiotensin Aldosterone Syst 2007;8:53.[Free Full Text]
  • Kang JJ, Toma I., Sipos A., McCulloch F., Peti-Peterdi J. Imaging the renin-angiotensin system: an important target of anti-hypertensive therapy. Adv Drug Deliv Rev 2006;58:824-33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Danser AHJ, Charney A., Feldman DL, Nussberger D., Fisher ND, Hollenberg NK The renin rise with aliskiren: it's simply stoichiometry. Hypertension 2008;51:e27-8.[Free Full Text]
  • Sica D., Andersen K., Oh BH, Arora V., Bush C., Keefe DL Effects of aliskiren on blood pressure and plasma renin activity persist after stopping treatment in patients with hypertension. J Clin Hypertens 2008;10(suppl A):A34-5 P69.[CrossRef]
  • Oh BH, Mitchell J., Herron JR, Chung J., Khan M., Keefe DL Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63.[Abstract/Free Full Text]
  • Keefe DL, Andersen K., Weinberger MH et al. Blood pressure lowering effects persist following the last dose of long-term therapy with aliskiren, an oral direct renin inhibitor. J Am Coll Cardiol 2007;49:372A P-1014-204.
  • Menard J., Guyene TT, Peyrard S., Azizi M. Conformational changes in prorenin during renin inhibition in vitro and in vivo. J Hypertens 2006;24:529-34.[Web of Science][Medline] [Order article via Infotrieve]
  • Nussberger J., Wuerzner G., Jensen C., Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2002;39:E1-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007;67:1767-92. 44. Luft FC, Weinberger MH. Antihypertensive therapy with aliskiren. Kidney Int 2007;73:679-83.
  • Van Tassell BW, Munger MA Aliskiren for renin inhibition: a new class of antihypertensives. Ann Pharmacother 2007;41:456-64.[Abstract/Free Full Text]
  • Jensen C., Herold P., Brunner HR Aliskiren: the first renin inhibitor for clinical treatment. Nat Rev Drug Discov 2008; 7:399-410.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Staessen JA, Li Y., Richart T. Oral renin inhibitors. Lancet 2006;368:1449-56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gradman AH, Schmieder RE, Lins RL, Nussberger J., Chiang Y., Bedigian MP Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-18.[Abstract/Free Full Text]
  • Kushiro T., Itakura H., Abo Y., Gotou H., Terao S., Keefe DL Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in Japanese patients with hypertension. Hypertens Res 2006; 29:997-1005.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schmieder RE, Philipp T., Guerediaga J. et al. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension. J Clin Hypertens 2007;9(suppl A):A182 P-436.
  • Andersen K., Weinberger MH, Egan B. et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008;26:589-99.[Web of Science][Medline] [Order article via Infotrieve]
  • Oparil S., Yarows SA, Patel S., Fang H., Zhang J., Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Pool JL, Schmieder RE, Azizi M. et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Stanton A., Jensen C., Nussberger J., O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43.[Abstract/Free Full Text]
  • Strasser RH, Puig JG, Farsang C., Croket M., Li J., van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007;21:780-7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Palatini P., Jung W., Shlyakhto E., Botha J., Bheda M., Keefe DL Comparative antihypertensive efficacy of the oral direct renin inhibitor aliskiren, irbesartan and ramipril after a missed dose: a double-blind ambulatory blood pressure monitoring study. J Am Coll Cardiol 2008;51:A-371 817-8.
  • Weir MR, Bush C., Anderson DR, Zhang J., Keefe DL, Satlin A. Antihypertensive efficacy, safety and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007; 1:264-77.[CrossRef]
  • Bourgault C., Senecal M., Brisson M., Marentette MA, Gregoire JP Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens 2005;19:607-13.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vaidyanathan S., Jarugula V., Dieterich H-A., Howard D., Dole WP Clinical pharmacokinetics and pharmacodynamics of aliskiren. Clin Pharmacokinet 2008;47:515-31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-52.[Abstract/Free Full Text]
  • Uresin Y., Taylor AA, Kilo C. et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8.[Abstract/Free Full Text]
  • Villamil A., Chrysant SG, Calhoun D. et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007;25:217-26.[Web of Science][Medline] [Order article via Infotrieve]
  • Drummond W., Munger MA, Essop MR, Maboudian M., Khan M., Keefe DL Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens 2007;9:742-50.[CrossRef]
  • Stergiou GS, Makris T., Papavasiliou M., Efstathiou S., Manolis A. Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy. J Hypertens 2005;23:883-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Chrysant SG, Murray AV, Hoppe UC et al. Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysis. Curr Med Res Opin 2008;24:1039-47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Parving HH, Persson F., Lewis JB, Lewis EJ, Hollenberg NK Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46.[Abstract/Free Full Text]
  • McMurray JJV, Pitt B., Latini R. et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008;1:17-24.[Abstract/Free Full Text]
  • Birkenhäger WH, Staessen JA Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007;370:195-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Perazella MA Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 2000;109:307-14.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Phillips CO, Kashani A., Ko DK, Francis G., Krumholz HM Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007;167:1930-6.[Abstract/Free Full Text]
  • Yusuf S., Teo KK, Pogue J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.[Abstract/Free Full Text]
  • Parving HH, Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.[Abstract/Free Full Text]
  • Jennings DL, Kalus JS, Coleman CI, Manierski C., Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabet Med 2007;24:486-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • MacKinnon M., Shurraw S., Akbari A., Knoll GA, Jaffey J., Clark HD Combination therapy with anangiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006;48:8-20.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kunz R., Friedrich C., Wolbers M., Mann JF Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.[Abstract/Free Full Text]
  • Kohn O. Review: combination therapy with renin angiotensin inhibitors reduces proteinuria more than single drugs alone in renal disease. Evid Based Med 2008;13:73.[Free Full Text]
  • Latini R., Masson S., Anand I. et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002;106:2454-8.[Abstract/Free Full Text]
  • Mancini GB, Dahlof B., Diez J. Surrogate markers for cardiovascular disease: structural markers. Circulation 2004;109:IV22-30.[Medline] [Order article via Infotrieve]
  • Gosse P. Left ventricular hypertrophy as a predictor of cardiovascular risk. J Hypertens Suppl 2005;23:S27-33.[Medline] [Order article via Infotrieve]
  • Solomon SD, Appelbaum E., Manning WJ et al. Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009;119:530-7.[Abstract/Free Full Text]
  • Lu H., Rateri DL, Feldman DL et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008;118:984-93.[Web of Science][Medline] [Order article via Infotrieve]
  • Imanishi T., Tsujioka H., Ikejima H. et al. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes. Hypertension 2008;52:563-72.[Abstract/Free Full Text]
  • Nussberger J., Aubert JF, Bouzourene K., Pellegrin M., Hayoz D., Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008;51:1306-11.[Abstract/Free Full Text]
  • Brown MJ Aliskiren. Circulation 2008;118:773-84.[Abstract/Free Full Text]
  • Duprez DA, Davis P., Botha J. The AGELESS Study: the effect of aliskiren vs ramipril alone or in combination with hydrochlorothiazide and amlodipine in patients > 65 years of age with systolic hypertension. Circulation 2008;118:S886-7.
  • Jordan J., Engeli S., Boye SW, Le Breton S., Keefe DL Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007;49:1047-55.[Abstract/Free Full Text]

Journal of Renin-Angiotensin-Aldosterone System, Vol. 10, No. 2, 65-76 (2009)
DOI: 10.1177/1470320309104662
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Sever, P. S
Right arrow Articles by Azizi, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sever, P. S
Right arrow Articles by Azizi, M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Blood Pressure Medicines
*High Blood Pressure
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement